Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/bjc2017367.pdf
Reference65 articles.
1. Ansell SM (2014) Brentuximab vedotin. Blood 124 (22): 3197–3200.
2. Bartlett NL, Sharman JP, Oki Y, Advani RH, Bello CM, Winter JN, Yang Y, Kennedy DA, Jacobsen ED (2013) A phase 2 study Of brentuximab vedotin in patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas: interim results in patients with DLBCL and other B-Cell lymphomas. Blood 122 (21): 848.
3. Bartlett NL, Smith MR, Siddiqi T, Advani RH, O'Connor OA, Sharman JP, Feldman T, Savage KJ, Shustov AR, Diefenbach CS, Oki Y, Palanca-Wessels MC, Uttarwar M, Li M, Yang J, Jacobsen ED (2017) Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. Leuk Lymphoma 58 (7): 1607–1616.
4. Beck A, Goetsch L, Dumontet C, Corvaia N (2017) Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov 16 (5): 315–337.
5. Bernardes GJ, Casi G, Trussel S, Hartmann I, Schwager K, Scheuermann J, Neri D (2012) A traceless vascular-targeting antibody-drug conjugate for cancer therapy. Angew Chem Int Ed Engl 51 (4): 941–944.
Cited by 275 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Preparation of trastuzumab-DM1 conjugate with a high drug-to-antibody ratio for breast cancer therapy;Nano Today;2024-02
2. Antibody–drug conjugates transform the outcome of individuals with low‐HER2‐expression advanced breast cancer;Cancer;2024-01-25
3. Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs;Cancers;2024-01-20
4. Therapeutic antibodies for the prevention and treatment of cancer;Journal of Biomedical Science;2024-01-12
5. Exploring the next generation of antibody–drug conjugates;Nature Reviews Clinical Oncology;2024-01-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3